Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ADC Bio Expands | Contract Pharma
Breaking News

ADC Bio Expands

Will invest $10m in cancer drug production

UK-based ADC Biotechnology has announced a $10 million plan to build a 1,500 square-meter manufacturing facility for advanced anti-cancer drugs.

The two-stage expansion program marks the transition of ADC Bio into GMP manufacturing of ADCs (antibody drug conjugates) and will create over 60 new science jobs at completion.

The investment responds to demand by drug developers and a shortage of capacity to make these new drugs in quantities sufficient for large-scale clinical trials.

Phase 1 of the project will come on stream in mid-2017, creating a 1,500 square-meter state-of-the-art, dual-stream facility for process development, manufacturing and quality testing of ADC drugs.

From both scale and regulatory perspectives, the new facility will be able to produce clinical trial and low-volume commercial quantities. Production will be in cutting edge cleanroom facilities, accommodating both ADC Bio’s proprietary Lock-Release technology and conventional, solution-phase production.

The facility will bring process development, manufacture, quality control, quality assurance and stability testing together under one roof at ADC Bio’s operational headquarters in St. Asaph, North Wales.

A projected second phase is planned to add another 2,500 square-meters of manufacturing space for larger scale clinical and commercial manufacturing.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters